Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin and Exercise-Induced Lipolysis
NCT03189732Phase 1Completed
- Sponsor
- Charles University
- Start
- Oct 2015
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM), sponsored by Charles University. Primary endpoint: Change in adipose tissue lipolysis in response to exercise. Started Oct 2015; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03189732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03189732.